[{"id":"36b66297-4fd6-4957-b2a6-306824388fd6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05152212","created_at":"2021-12-09T18:00:30.683Z","updated_at":"2024-07-02T16:35:08.680Z","phase":"Phase 1","brief_title":"Study of LVGN7409 (CD40 Agonist Antibody) in Locally Advanced, Metastatic or Recurrent/Refractory Malignancy","source_id_and_acronym":"NCT05152212","lead_sponsor":"Lyvgen Biopharma Holdings Limited","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dalnicastobart (LVGN7409)"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 09/29/2021","start_date":" 09/29/2021","primary_txt":" Primary completion: 12/06/2023","primary_completion_date":" 12/06/2023","study_txt":" Completion: 12/06/2023","study_completion_date":" 12/06/2023","last_update_posted":"2024-04-19"},{"id":"04df3049-aecf-4362-a49a-2285288f64a1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05075993","created_at":"2021-10-13T16:58:12.200Z","updated_at":"2024-07-02T16:35:11.360Z","phase":"Phase 1","brief_title":"Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors","source_id_and_acronym":"NCT05075993","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD40","pipe":"","alterations":" ","tags":["CD40"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • albumin-bound paclitaxel • cyclophosphamide • cyclophosphamide intravenous • dalnicastobart (LVGN7409) • exlinkibart (LVGN6051) • pradusinstobart (LVGN3616)"],"overall_status":"Recruiting","enrollment":" Enrollment 352","initiation":"Initiation: 11/12/2021","start_date":" 11/12/2021","primary_txt":" Primary completion: 02/02/2027","primary_completion_date":" 02/02/2027","study_txt":" Completion: 02/02/2027","study_completion_date":" 02/02/2027","last_update_posted":"2024-04-04"}]